ChemoCentryx said it has identified a novel drug candidate to treat inflammatory skin diseases.

The investigational new drug-coded CCX832 is an orally administered small molecule antagonist, which will undergo clinical development by early next year.

CCX832 is the fourth and final drug candidate under ChemoCentryx’s collaboration with GlaxoSmithKline (GSK), which triggered a $5m milestone payment by the latter.

With the acceptance of CCX832 by GSK, ChemoCentryx has delivered all four clinical development candidates as defined by the partners three and a half years ago.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData